Why ACADIA Pharmaceuticals Inc.’s (ACAD) Stock Is Down 5.25%
As of Friday, September 25, ACADIA Pharmaceuticals Inc.’s ACAD share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name Acadia Pharmaceuticals Inc. in 1997. Acadia Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Commentary & Analysis
Why ACADIA Pharmaceuticals Inc.’s (ACAD) Stock Is Down 13.23%
As of Thursday, September 24, ACADIA Pharmaceuticals Inc.’s ACAD share price has dipped by 13.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Xencor, Inc. Stock?
Learn more about whether ACADIA Pharmaceuticals Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why ACADIA Pharmaceuticals Inc.’s (ACAD) Stock Is Up 6.06%
As of Wednesday, August 05, ACADIA Pharmaceuticals Inc.’s ACAD share price has surged by 6.06%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About ACADIA Pharmaceuticals Inc.'s Q3 Earnings
ACADIA Pharmaceuticals Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (ACAD) missed or beat analyst's expectations.Tudor Pop
Financial Summary
| Share Statistics | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,344.5 | $237.5 | 62% |
|
| Shares Out (Mil) | 172.9 | 53.9 | 73% |
|
| Institutional Ownership | 99.3% | 93.1% | 87% |
|
| Float (Mil) | 128.4 | 41.4 | 65% |
|
| Beta | 0.85 | 0.95 | 51% |
|
| Avg Daily Volume (000s) | 2,221 | 628 | 83% |
|
| Price Change (52-week) |
(5.9%) | 49.0% | 47% |
|
| Growth | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.4% | 12.4% | 80% |
|
| Net Income (5yr) | 27.6% | (10.2%) | 83% |
|
| EPS (5yr) | 26.9% | 15.7% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.4%) | (15.7%) | 26% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 14 | |
| Current EPS | $0.183 | $0.596 | $0.904 | |
| Month Ago EPS | $0.185 | $0.599 | $0.890 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.126 | $0.381 | $0.891 | |
| Year/Year Chg | 1.7% | (74.1%) | (24.6%) | |
| Financials | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,139 | $37 | 52% |
|
| Net Income (TTM) (Mil) | $381 | ($44) | 75% |
|
| EPS (TTM) | $2.235 | ($1.600) | 73% |
|
| Operating Cash Flow (TTM) (Mil) | $160 | ($33) | 56% |
|
| Net Cash Flow (TTM) (Mil) | $130 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $4,080 | $174 | 59% |
|
| Valuation | ACAD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.56 | 2.27 | 62% |
|
| P/E | 8.8 | 19.7 | 13% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 1.0 | 15% |
|
| Ratios | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.1% | 66.9% | 75% |
|
| Net Margin | 33.4% | (75.3%) | 91% |
|
| ROA | 25.6% | (47.7%) | 98% |
|
| ROE | 35.7% | (55.0%) | 90% |
|
| Liabilities to Assets | 25.0% | 29.4% | 17% |
|
| F-Score | 6 | 2 | 67% |
|
Passing Stock Screens
As of 10/12/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
FACTOR STRATEGY
Return on Equity Screen
Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE.
| Performance Since Inception: | 12.7% |
| +/- S&P 500: | +5.2 |
